Clinical trials: Masseter
Masseter Muscle Hypertrophy
Botulinum Toxin Type A (BOTOX®) Treatment of Masseter Muscle Hypertrophy
This study will evaluate the safety and efficacy of a range of doses of botulinum toxin Type A (BOTOX®) for the treatment of patients with bilateral Masseter Muscle Hypertrophy (MMH).
- Trial name
- NCT02010775
- Testing
- botulinum toxin Type A, Normal saline
- Where
- 14 sites in Australia, Canada and 1 more
- Volunteers
- 187 people
- Sponsor
- Allergan
Masseter Muscle Prominence
BOTOX® (onabotulinumtoxinA) Treatment of Masseter Muscle Prominence
Based on the results of the Phase 2 Study 191622-130 [NCT02010775], the current Phase 2b study is designed to further evaluate the safety and efficacy of BOTOX® for the treatment of Masseter Muscle Prominence (MMP) in adults.
- Trial name
- NCT03861936
- Testing
- OnabotulinumtoxinA, Normal saline
- Where
- 14 sites in United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Allergan
Healthy Volunteers
Reliability of a Masseter Muscle Prominence Scale and Lower Facial Shape Classification
This study will evaluate the inter-rater and intra-rater reliability of a Masseter Muscle Prominence Scale for evaluating a patient's muscle prominence and a Lower Shape Classification for evaluating a patient's lower facial…
- Trial name
- NCT01821534
- Testing
- No Intervention
- Where
- United States
- Volunteers
- 201 people, healthy volunteers welcome
- Sponsor
- Allergan
Masseter Muscle Prominence
BOTOX® Treatment for Adults With a Wide Lower Face Due to Masseter Muscle Prominence
This study is designed to evaluate the safety and effectiveness of administering BOTOX for the treatment of Masseter Muscle Prominence (MMP) in adults.
- Trial name
- NCT04073303
- Testing
- Botulinum Toxin Type A
- Where
- 21 sites in Canada, China and 1 more
- Volunteers
- 377 people
- Sponsor
- AbbVie